Bausch + Lomb Financial Report

Bausch + Lomb faced challenges in the fourth quarter, leading to a widened net loss due to increased interest and product launch expenses. Despite this setback, the eye-health company exceeded analyst expectations with strong revenue performance across its segments.

Financial Overview

• Reported net loss of $54 million, or 15 cents per share, compared to a loss of $1 million in the same period last year.
• Adjusted earnings stood at 24 cents per share, surpassing analysts' projected decline to 17 cents per share.
• Revenue increased to $1.17 billion from $996 million, outperforming anticipated growth to $1.11 billion.

Segment Performance

• Pharmaceutical unit saw significant growth, rising by 67% to $307 million.
• Vision care, the largest segment, increased by 8% to $662 million.
• Surgical segment rose by 9% to $204 million.

Future Outlook

Bausch + Lomb anticipates full-year revenue growth between 12% and 14%, reaching $4.6 billion to $4.7 billion in constant currency terms. Adjusted earnings before interest, taxes, depreciation, and amortization are expected to range from $840 million to $890 million, marking an improvement from the $738 million achieved in 2023.

CEO Statement

"We exceeded our revenue growth expectations in the fourth quarter of 2023, which sets a positive trajectory for the year ahead," stated Chief Executive Brent Saunders.

The company remains focused on navigating challenges and driving sustainable growth in the coming year.

Adriano Marchese